Multi-Center, Open-Label, Dose-Escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma.

Trial Profile

Multi-Center, Open-Label, Dose-Escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2014

At a glance

  • Drugs Rabacfosadine (Primary)
  • Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Dec 2010 Planned end date changed from 1 Sep 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
    • 13 Dec 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top